Singulex, Inc. Teams With Wyeth to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
Published: Nov 27, 2007
HAYWARD, Calif., Nov. 27 /PRNewswire/ -- Singulex Inc. today announced that it is collaborating with researchers at Wyeth Research to develop immunoassays on the company's Erenna(TM) system. Singulex has installed the Erenna system at Wyeth as part of its Erenna Technology Access Program (ETAP) and has begun optimizing assays that will allow Wyeth to accurately and precisely measure specific biomarkers in human blood.
"Biomarkers play an important role in the evaluation of compounds in both drug discovery and development, and we are keenly interested in applying new and improved technologies in the measurements of biomarkers," said Ole Vesterqvist, Ph.D., senior director of the Biomarker Laboratory in Clinical Translational Medicine at Wyeth. "For example, with the right biomarker and technology, one can study the effects of a therapeutic intervention in clinical studies. However, many biomarkers are present in human blood at extremely low concentrations, making it difficult to accurately and precisely measure. Singulex has provided us with a new technology for detection of biomarkers at very low concentrations and we are currently validating several assays in our laboratory that should help us guide our clinical programs."
Singulex's proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company's flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species. Singulex was the first to identify and quantify normal levels and small changes of cardiac troponin I, a protein biomarker used to detect cardiotoxicity and heart attacks, in human plasma.
"Singulex's technology extends the clinical utility of new and existing biomarkers by removing the limits of detection," said Philippe Goix, Ph.D., president and CEO of Singulex. "The ability to detect normal and deviations from normal levels of biomarkers will enable better determination of therapeutic index for drug developers and researchers and help shorten the time to select and develop new therapies."
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Hayward, California. To learn more about Singulex, please visit us at http://www.singulex.com.
The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.
CONTACT: Carolyn Hawley of Porter Novelli Life Sciences, +1-619-849-5375,
firstname.lastname@example.org, for Singulex Inc.
Web site: http://www.singulex.com/